GlobeNewswire

Resilinc study: 32% of the S&P 500 impacted in 2017

Dela

Resilinc Publishes 2017 EventWatch® Supply Chain Disruption Annual Report

SAN FRANCISCO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Resilinc, a global provider of supply chain resiliency solutions, released its 2017 EventWatch® Supply Chain Disruption Annual Report today.  The report identifies that global supply chain disruptions roughly doubled in the past year, potentially impacting 32% of S&P 500 company's supply chains and negatively effecting the US economy.

In 2017, natural disasters and weather-related events proved to be a considerable source of disruption across the globe and especially the United States, which for the first time became the most impacted region in the world.  In addition to natural disasters, factory fires remain a significant risk to supply chains, and cyber-attacks increased substantially in 2017.

The annual report is a study of the prior year's supply chain disruption events: natural disasters, extreme weather, fires, environmental hazards, geopolitical occurrences, and other business developments.  These events are tracked and their impact upon manufacturing supply chains assessed by the Resilinc technology and expert teams.  The Resilinc EventWatch® service provides 24x7 alerting and notifications to subscribers tracking their exposure.  Hundreds of millions of news alerts across over 100,000 sources in 44 languages were monitored and analyzed in 2017 alone.

"This should be a wake-up call for business leaders around the globe," states Bindiya Vakil, CEO of Resilinc.  "2017 was a turbulent year for US companies and their supply chains, causing a hidden drag that must be addressed.  With 32% of S&P 500 companies potentially impacted, the economic damage is enormous."  Hurricanes Harvey, Irma, and Maria alone contributed to significant impacts to business in 2017, finds the report. 

In 2017, Resilinc EventWatch contacted more than 19,000 unique suppliers for potential impacts, which generated responses from 53% of those suppliers contacted.  "When an event occurs, action must be taken by all members of the supply chain, to ensure that appropriate steps are taken to avoid any potential impacts.  The faster and more efficiently these steps are taken, the less the overall economic consequences," said Shahzaib Khan, Director of EventWatch at Resilinc.

The annual report analyzed incidents by risk type, industry, geography, disruption potential, and month for 2016 and 2017 for comparison purposes by industry and geography.  The report highlights global supply chain risk trends through a variety of lenses and aids supply chain planning for 2018 and beyond.

Key report highlights include:

  • The top 5 events of 2017 in terms of impact to businesses were:
    1. Late winter storm in the Northeast USA, March
    2. Weather related damage closed the US/Mexico Laredo border, May
    3. Hurricane Harvey in USA, August
    4. Hurricane Irma in USA, September
    5. Hurricane Maria in Puerto Rico, September 
  • For the first time, North America was the most disrupted region by natural disasters.
  • Factory fire/explosion represented the majority of EventWatch bulletins in 2017 with 18% of bulletins notified.
  • Cyber-attacks increased substantially, particularly of the ransomware variety.
  • The automotive industry was the most disrupted industry as it saw an increase of 30% bulletins published. All industries observed increases of around 300 bulletins or greater in 2017.

For more information
An electronic version of the annual report is available at http://info.resilinc.com/eventwatch-2017-annual-report-0

The Resilinc EventWatch service is available at https://info.resilinc.com/eventwatch-professional-enterprise

About Resilinc
Resilinc is the leading global supplier of supply chain risk and resiliency solutions.  Industry leading companies such as IBM, General Motors, EMC, Amgen and Western Digital rely on Resilinc to plan for potential supply chain failures, and to protect revenue despite supply chain disruptions worldwide.  For more information about our solutions, please visit www.resilinc.com.

Contact:

Grover Righter, Chief Marketing Officer

Marketing.Team@Resilinc.com

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resilinc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum